- PR Newswire•10 hours agoSobi and Horizon Pharma enter five-year distribution agreement for Ravicti® and Ammonaps® outside the United States
Swedish Orphan Biovitrum AB (publ) (Sobi™) and Horizon Pharma plc (HZNP) ("Horizon") today announced that the companies have entered into a five-year distribution agreement for Ravicti® (glycerol phenylbutyrate) in European countries, including United Kingdom, Germany, France, Italy and Spain and for Ammonaps® (sodium phenylbutryate) in the same European countries and certain Middle Eastern countries. Under the agreement, Sobi will have exclusive marketing, sales and distribution rights for the two medicines in the territory until 31 December 2021. Horizon has the ability to terminate the agreement after two years subject to certain pre-defined termination fees. Sobi currently distributes Ravicti in certain Middle Eastern countries and Ammonaps in certain European and Middle Eastern countries.
- Business Wire•4 days agoData Reinforcing the Long-Term Safety and Efficacy of Extended Half-Life Hemophilia Therapies ELOCTATE® and ALPROLIX® Highlighted at 58th ASH Meeting
Biogen and Swedish Orphan Biovitrum AB will present new data, including updated longitudinal safety and efficacy findings from phase 3 and extension studies, on the companies’ extended half-life therapies, ELOCTATE® for hemophilia A and ALPROLIX® for hemophilia B, at the 58th American Society of Hematology Annual ...
- MarketWatch•12 days ago
European stocks closed higher Friday, a move that solidified a rise for blue-chip equities for a third consecutive week.
SOBI.ST : Summary for Swedish Orphan Biovitrum AB - Yahoo Finance
Swedish Orphan Biovitrum AB (SOBI.ST)
Stockholm - Stockholm Delayed Price. Currency in SEK
Add to watchlist
|Day's Range||97.45 - 99.95|
|52 Week Range||89.50 - 136.60|
|PE Ratio (TTM)||37.61|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|